Orris

Mdr and xdr tb

Reading File
Finding Sources
Finding Sources
Searching PubMed

"MDR-TB" OR "XDR-TB" AND treatment

Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Searching Images

MDR-TB XDR-TB drug treatment regimen WHO groups

This infographic showcases the user interface of the TB-DRC-DSS, a web-based decision support system for tuberculosis (TB) detection and drug resistance classification, displayed across four mobile device frames. Each screen follows a consistent layout: a header titled 'TB DETECTION AND DRUG RESISTANT-TB CLASSIFICATION SYSTEM', an image upload button, a central posterior-anterior (PA) chest X-ray (CXR), and a diagnostic results section at the bottom. The visual demonstrates four distinct clinical categories: Drug-Susceptible TB (DS-TB), Drug-Resistant TB (DR-TB), Multidrug-Resistant TB (MDR-TB), and Extensively Drug-Resistant TB (XDR-TB). Each X-ray displays varying pulmonary pathologies, including consolidations, cavitary lesions, and diffuse opacities. Below each radiographic image, the system provides a specific 'CLASS' label and a 'RECOMMENDED REGIMEN' according to established treatment protocols (e.g., 2HRZE/4HR for DS-TB or Bedaquiline-containing regimens for MDR-TB). The tool is designed for pulmonologists and TB specialists to integrate diagnostic imaging with pharmaceutical decision-making at the point of care.

This infographic showcases the user interface of the TB-DRC-DSS, a web-based decision support system for tuberculosis (TB) detection and drug resistance classification, displayed across four mobile device frames. Each screen follows a consistent layout: a header titled 'TB DETECTION AND DRUG RESISTANT-TB CLASSIFICATION SYSTEM', an image upload button, a central posterior-anterior (PA) chest X-ray (CXR), and a diagnostic results section at the bottom. The visual demonstrates four distinct clinical categories: Drug-Susceptible TB (DS-TB), Drug-Resistant TB (DR-TB), Multidrug-Resistant TB (MDR-TB), and Extensively Drug-Resistant TB (XDR-TB). Each X-ray displays varying pulmonary pathologies, including consolidations, cavitary lesions, and diffuse opacities. Below each radiographic image, the system provides a specific 'CLASS' label and a 'RECOMMENDED REGIMEN' according to established treatment protocols (e.g., 2HRZE/4HR for DS-TB or Bedaquiline-containing regimens for MDR-TB). The tool is designed for pulmonologists and TB specialists to integrate diagnostic imaging with pharmaceutical decision-making at the point of care.

Treatment regimen for multi-drug resistant TB <table><thead><tr><th colspan="2">Treatment regimen for multi-drug resistant TB</th></tr><tr><td colspan="2">Treat multi-drug resistant TB with an individualised treatment regime including at least five effective tuberculosis medicines during the intensive phase, including pyrazinamide and four core second-line tuberculosis medicines*.</td></tr></thead><tbody><tr><td>Group A<br>Fluoroquinolones</td><td>Levofloxacin, Moxifloxacin and Gatifloxacin</td></tr><tr><td>Group B<br>Second-line injectables</td><td>Amikacin, Capreomycin, Kanamycin and Streptomycin**</td></tr><tr><td>Group C<br>Other second-line agents</td><td>Ethionamide/ Prothionamide, Cycloserine/Terizidone, Linezolid and Clofazimine</td></tr><tr><td>Group D<br>Add-on agents (not part of the core MDR-TB regime)</td><td>D1: Pyrazinamide, Ethambutol, and High-dose isoniazid<br>D2: Bedaquiline and Delamanid<br>D3: p-aminosalicylic acid, Imipenem-cilastatin, Meropenem, Amoxicillin-clavulanate and Thioacetazone***</td></tr></tbody></table>

Treatment regimen for multi-drug resistant TB <table><thead><tr><th colspan="2">Treatment regimen for multi-drug resistant TB</th></tr><tr><td colspan="2">Treat multi-drug resistant TB with an individualised treatment regime including at least five effective tuberculosis medicines during the intensive phase, including pyrazinamide and four core second-line tuberculosis medicines*.</td></tr></thead><tbody><tr><td>Group A<br>Fluoroquinolones</td><td>Levofloxacin, Moxifloxacin and Gatifloxacin</td></tr><tr><td>Group B<br>Second-line injectables</td><td>Amikacin, Capreomycin, Kanamycin and Streptomycin**</td></tr><tr><td>Group C<br>Other second-line agents</td><td>Ethionamide/ Prothionamide, Cycloserine/Terizidone, Linezolid and Clofazimine</td></tr><tr><td>Group D<br>Add-on agents (not part of the core MDR-TB regime)</td><td>D1: Pyrazinamide, Ethambutol, and High-dose isoniazid<br>D2: Bedaquiline and Delamanid<br>D3: p-aminosalicylic acid, Imipenem-cilastatin, Meropenem, Amoxicillin-clavulanate and Thioacetazone***</td></tr></tbody></table>

This infographic depicts a mobile-based diagnostic support system for tuberculosis (TB) management, presenting three separate smartphone interface frames. Each frame features a posterior-anterior (PA) chest X-ray (CXR) with AI-generated classifications and treatment regimens. The first image shows significant opacification and consolidation in the upper lung fields, classified as Drug-Resistant TB (DR-TB), with complex multidrug regimens listed. The second image displays relatively clear lung fields with normal vascular markings, classified as Drug-Susceptible TB (DS-TB), suggesting early-stage disease or a normal baseline, paired with a standard '2HRZE/4HR' regimen. The third image illustrates mild interstitial markings and apical opacities, classified as Multi-Drug Resistant TB (MDR-TB), recommending a shorter all-oral bedaquiline-containing regimen. This visual demonstrates the clinical application of deep learning algorithms in identifying TB drug-response phenotypes (DS, DR, MDR) and providing automated therapeutic guidance based on WHO protocols for infectious disease specialists and healthcare providers.

This infographic depicts a mobile-based diagnostic support system for tuberculosis (TB) management, presenting three separate smartphone interface frames. Each frame features a posterior-anterior (PA) chest X-ray (CXR) with AI-generated classifications and treatment regimens. The first image shows significant opacification and consolidation in the upper lung fields, classified as Drug-Resistant TB (DR-TB), with complex multidrug regimens listed. The second image displays relatively clear lung fields with normal vascular markings, classified as Drug-Susceptible TB (DS-TB), suggesting early-stage disease or a normal baseline, paired with a standard '2HRZE/4HR' regimen. The third image illustrates mild interstitial markings and apical opacities, classified as Multi-Drug Resistant TB (MDR-TB), recommending a shorter all-oral bedaquiline-containing regimen. This visual demonstrates the clinical application of deep learning algorithms in identifying TB drug-response phenotypes (DS, DR, MDR) and providing automated therapeutic guidance based on WHO protocols for infectious disease specialists and healthcare providers.

I now have excellent comprehensive data. Let me compile the full answer.

MDR-TB and XDR-TB: A Comprehensive Overview

Definitions

TermDefinition
MDR-TBM. tuberculosis resistant to at least isoniazid (INH) AND rifampicin (RIF) - the two most potent first-line drugs
Pre-XDR-TBMDR-TB + additional resistance to either a fluoroquinolone OR a second-line injectable (amikacin, kanamycin, capreomycin) - but not both
XDR-TBMDR-TB + resistance to a fluoroquinolone AND at least one second-line injectable agent (amikacin, kanamycin, capreomycin, or streptomycin)
Updated 2021 WHO Definition: XDR-TB now also includes MDR-TB with resistance to fluoroquinolones AND bedaquiline/linezolid, reflecting their central role in modern regimens.
  • Approximately 20% of M. tuberculosis isolates globally meet the MDR-TB definition
  • Conversion rates approach 50% in exposed individuals - MDR-TB strains are highly infectious
  • XDR-TB carries significantly poorer outcomes and higher mortality, found in New York, California, Italy, Iran, India, and former Soviet states
  • Tintinalli's Emergency Medicine, p. 1004-1006
  • Goldman-Cecil Medicine, p. 3167-3168

Pathogenesis of Resistance

Resistance develops through spontaneous genetic mutation, almost always selected by:
  • Inadequate drug regimens (monotherapy or suboptimal combinations)
  • Poor adherence / incomplete courses
  • Subtherapeutic drug levels
The cardinal principle: never treat TB with a single drug - always combine agents to prevent selection pressure.

Risk Factors for Suspecting Drug-Resistant TB

  • Prior TB treatment (especially incomplete or non-standard)
  • Not receiving directly observed therapy (DOT)
  • Close contact with known MDR-TB patient
  • Origin from high-burden regions (former Soviet states, South Africa, India, China)
  • Known INH resistance in community >4%
  • Lack of culture conversion after 3-4 months of standard therapy
  • Progressing radiographic findings despite therapy
  • Murray & Nadel's Respiratory Medicine, p. 2535-2556

Diagnosis

Rapid molecular testing:
  • GeneXpert MTB/RIF - detects M. tuberculosis AND RIF resistance simultaneously; results in ~2 hours
  • CDC Molecular Detection of Drug Resistance Service - detects mutations for INH, RIF, and second-line drugs
Confirmatory:
  • Culture-based drug susceptibility testing (DST) - gold standard
  • Whenever RIF resistance is identified, full second-line DST should be requested
  • Fluoroquinolone susceptibility must be evaluated whenever INH resistance is found

Treatment of MDR-TB

WHO Drug Grouping for MDR/RR-TB

GroupDrugsPrinciple
A (all three required)Levofloxacin OR moxifloxacin, Bedaquiline, LinezolidInclude all 3 unless contraindicated
B (add both if possible)Clofazimine, Cycloserine or terizidoneAdd both unless contraindicated
C (fill regimen to ≥4-5 drugs)Ethambutol, Delamanid, Pyrazinamide, Meropenem + amoxicillin-clavulanate, Amikacin, Ethionamide/prothionamideUse when Group A/B agents cannot be used
  • Goodman & Gilman's Pharmacological Basis of Therapeutics, Table 65-6

Standard Long Regimen (MDR-TB)

  • 4-5 active drugs during an intensive phase, then 4 active drugs in continuation phase
  • Total treatment: 18-20 months (after culture conversion)
  • Under expert guidance with monthly sputum cultures to monitor response

WHO Short-Course Regimen (9-12 months)

  • Eligibility: fluoroquinolone-susceptible, no prior second-line drug exposure
  • Drugs: Bedaquiline + fluoroquinolone + clofazimine + pyrazinamide + ethambutol + high-dose INH + ethionamide
  • Excludes: pregnancy, disseminated TB, treatment intolerance
  • Goldman-Cecil Medicine, p. 3166-3167

Treatment of XDR-TB: BPaL Regimen

The landmark Nix-TB trial and FDA approval established the BPaL regimen:
DrugDoseDuration
Bedaquiline (B)400 mg daily x 2 weeks, then 200 mg 3x/week26 weeks
Pretomanid (Pa)200 mg daily26 weeks
Linezolid (L)1200 mg daily (reduce to 600 mg for toxicity, 300 mg for myelosuppression/neuropathy/optic neuropathy)26 weeks
  • Outcome: BPaL achieved 90% favorable outcomes in XDR-TB or complicated MDR-TB (Nix-TB trial)
  • Total duration: ~6 months - dramatically shorter than historical 18-24 month regimens
  • FDA-approved: Pretomanid for XDR-TB in combination with bedaquiline and linezolid
BPaLM = BPaL + Moxifloxacin - used for fluoroquinolone-susceptible MDR-TB; recommended by WHO 2022 guidelines as preferred for eligible patients.
  • Murray & Nadel's, p. 3433-3437; Goldman-Cecil, p. 3168; Katzung, p. 3215-3221

Mechanisms of Key Drugs

DrugMechanism
Levofloxacin / MoxifloxacinInhibit bacterial DNA gyrase (topoisomerase II/IV) - bactericidal, concentration-dependent killing
BedaquilineInhibits mycobacterial ATP synthase - active against both replicating AND dormant bacilli
LinezolidInhibits bacterial protein synthesis (binds 23S rRNA of 50S subunit)
PretomanidBicyclic nitroimidazole - generates reactive nitrogen intermediates (active against anaerobic bacilli); also inhibits mycolic acid synthesis
DelamanidDihydro-nitroimidazooxazole - inhibits mycolic acid synthesis; licensed by EMA for MDR-TB
ClofazimineBinds mycobacterial DNA, generates reactive oxygen species
CycloserineInhibits D-alanine racemase/ligase - blocks cell wall peptidoglycan synthesis

Key Treatment Principles

  1. Never add a single new drug to a failing regimen - this selects resistance to that drug; always change multiple drugs simultaneously
  2. Only use drugs with documented/likely susceptibility - never add drugs with known resistance
  3. Expert consultation is mandatory for all drug-resistant TB cases
  4. Monitor monthly sputum cultures - if cultures remain positive at 3 months, repeat susceptibility testing
  5. Surgery: partial resection can be considered for localized pulmonary MDR-TB refractory to medical therapy in selected patients
  6. Success rates for MDR-TB with conventional regimens rarely exceed 60%; BPaL has improved outcomes for XDR-TB dramatically

Special Situations

MDR-TB in HIV

  • Use rifabutin (RFB) instead of rifampicin to reduce CYP3A4 interactions with antiretrovirals
  • Dolutegravir 50 mg twice daily is compatible with rifampicin
  • Watch for IRIS (immune reconstitution inflammatory syndrome) - treat severe cases with prednisone 1.25 mg/kg/day for 2-4 weeks, then taper

MDR-TB in Pregnancy

  • Avoid aminoglycosides (ototoxicity to fetus)
  • Bedaquiline and linezolid: limited data; risk-benefit discussion required
  • BPaL regimen: pregnancy is an exclusion criterion for short-course regimens

Children

  • Lower sputum yield; diagnosis harder
  • Risk of miliary TB, TB meningitis, and disseminated disease is higher

MDR-TB Drug Regimen Chart

MDR-TB Treatment Regimen WHO Groups

Recent Evidence (2025-2026)

Summary: MDR vs XDR Quick Reference

FeatureMDR-TBXDR-TB
ResistanceINH + RIFMDR + fluoroquinolone + injectable
Treatment duration9-20 months6 months with BPaL
Core drugsFQ + Bedaquiline + LinezolidBedaquiline + Pretomanid + Linezolid
OutcomesSuccess ~60-70% with modern regimens~90% with BPaL (Nix-TB)
MortalityModerateHistorically high; improved with BPaL
This is a shared conversation. Sign in to Orris to start your own chat.